ClinicalTrials.gg
RecruitingNCT06136728AmpPTUpdated Nov 6, 2026

Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

A Phase 3 interventional study of Dalfampridine 10 MG [Ampyra] and Physical therapy in Multiple Sclerosis, sponsored by MGH Institute of Health Professions. Recruiting at 1 site in United States. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by MGH Institute of Health Professions · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 6, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies testing 4-Aminopyridine in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. 4-Aminopyridine · Multiple Sclerosis.

Planned enrollment
17th of 27
48 · median 64
Started
2024
the only one that year
Phase 3
9 of 27
1 open now
Registered
27th of 27
by date

Among the 27 studies testing 4-Aminopyridine in Multiple Sclerosis, this one is the 17th largest by planned enrollment, is the only one that started in 2024, is one of 9 in phase 3, and was the 27th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 27 studies testing 4-Aminopyridine in Multiple Sclerosis is open now, in 1 country.

By country, each count listing its studies:

About 4-Aminopyridine

4-Aminopyridine: first FDA approval 2010 (AMPYRA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 25 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing 4-Aminopyridine in Multiple Sclerosis, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are:

  • Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?
  • Is the combined treatment associated with better outcomes than the medication (dalfampridine) on its own?
  • How do the individual treatments (dalfampridine, physical therapy) alone compare to each other?

Participants with MS-related mobility deficits will:

  • Receive 6 weeks of dalfampridine treatment to assess the effects of this treatment.
  • After stopping the medication for 2 weeks, the investigators will re-evaluate walking, then randomly assign individuals to a 6-week physical therapy program.
  • Half of the participants will receive physical therapy while resuming dalfampridine treatment. The other half of the participants will receive physical therapy without resuming the medication.

Researchers will compare the combination treatment group (medication plus physical therapy) to the physical therapy only group to see if the combined treatment improves walking-related function. Approximately 3 months after finishing the physical therapy program, participants will undergo a final evaluation to see if the treatment effects have been maintained.

Read the detailed description

Multiple sclerosis (MS) is a degenerative disease process that disrupts the transmission of nerve impulses, resulting in a range of neurological signs and symptoms. Walking-related impairment is one of the most common symptoms, reported to affect more than 90% of people with MS. The leading non-pharmacological intervention for walking-related deficits in people with MS is rehabilitation, such as physical therapy. Rehabilitation is believed to restore function through experience-dependent neuroplasticity. There is strong evidence that physical therapy can improve mobility-related function in people with MS, and emerging evidence that motor-relearning approaches to rehabilitation may be associated with changes in brain structure and function that correlate with improvements in functional performance. The leading pharmacological intervention for walking-related deficits in people with MS is dalfampridine. Dalfampridine improves motor function by increasing nerve conduction through demyelinated axons, however, dalfampridine alone is not likely to generate neuroplastic changes needed for lasting benefits, because neural plasticity requires salient and task-specific practice with high repetition at adequate intensity, as well as complex environments that stimulate opportunities for movement to facilitate synthesis of neurotrophic factors. Indeed, the treatment effects of dalfampridine are reversed as soon as the treatment was discontinued. However, it is possible that improved nerve conduction velocity provided by dalfampridine may accelerate neuroplasticity generated from rehabilitation. Yet, combining dalfampridine with concurrent rehabilitation has never been studied. The objective of the proposed study is to test our central hypothesis that providing a motor-relearning physical therapy intervention in combination with dalfampridine will produce superior gains to either intervention alone in mobility through augmented neuroplasticity.

Aim 1 will determine if dalfampridine can augment the effects of physical therapy in restoring function in people with MS by comparing the combined intervention to physical therapy without dalfampridine. Aim 2 will explore the comparative effectiveness between the combined intervention with dalfampridine alone, and between physical therapy alone and dalfampridine alone. In Aim 3, the investigators will investigate mechanisms of treatment effects by evaluating functional connectivity before and after each intervention arm. Exploratory Aim 4 will examine whether there are specific clinical and personal factors associated with treatment responsiveness to each type of treatment. The primary efficacy outcome will be percent change from baseline in Timed 25-Foot Walk to enable direct comparison to previous dalfampridine studies. A range of secondary and tertiary clinical outcomes, both objective and self-reported, will examine restoration of function (objective and perceived) beyond just walking speed.

The investigators will enroll 48 participants with MS-related mobility deficits and EDSS ≤6.5. In the first treatment phase, all participants will receive 6 weeks of dalfampridine treatment to assess the effects of this treatment and determine individual responder status for stratified randomization in phase 2. Following 2-week dalfampridine washout and new off-drug baseline assessment, stratified randomization will allocate participants to either 6 weeks of physical therapy with resumed dalfampridine or 6 weeks of physical therapy without dalfampridine. Outcomes will be reassessed after the physical therapy treatment phase. This project tests a novel combination of two traditional interventions to improve mobility in people with MS, with specific aims that investigate both restoration of function and mechanisms of treatment effects using brain imaging outcomes. These two leading, yet distinct approaches for improving mobility in people with MS, may have complementary mechanisms of action leading to enhanced outcomes when combined. The findings generated by this research will inform the design of further studies exploring longer-term outcomes and disease progression trajectories associated with the interventions found to be most effective and tolerable for individuals with MS in this stage of the research.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of MS
  • Expanded Disability Status Scale (EDSS) 6.5 or less
  • Timed 25-Foot Walk 6-45 seconds (average of 2 trials)
  • Able to stand unsupported for at least 10 seconds
  • 23 or higher
  • Relapse free for at least 3 months
  • Not currently taking dalfampridine or not previously taken and discontinued due to adverse reactions
  • Not currently receiving physical therapy

Exclusion criteria

Exclusion Criteria:

  • Co-existing neurological disorders or orthopedic conditions affecting mobility and physical activity
  • Unable to follow a 3-step verbal command in English
  • Hospitalization for any reason in the last 3 months
  • Uncontrolled hypertension or diabetes
  • History of seizures
  • Renal impairment
  • Women who are breastfeeding, pregnant, or trying to become pregnant
  • to magnetic resonance imaging (MRI; to be excluded from MRI procedures but may participate if all other criteria are met)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Dalfampridine only

    10 mg tablet twice per day

    Drug: Dalfampridine 10 MG [Ampyra]

  • Active comparator
    Physical therapy

    One-on-one outpatient physical therapy twice per week

    Behavioral: Physical therapy

  • Active comparator
    Dalfampridine plus physical therapy

    10 mg tablet twice per day while receiving one-on-one outpatient physical therapy twice per week

    Other: Dalfampridine plus physical therapy

Interventions

  • Drug4-AminopyridineStudies of 4-Aminopyridine4-Aminopyridine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dalfampridine (10 mg) every 12 hours for 6 weeks.

    Also known as: Ampyra

  • BehavioralPhysical therapy

    Physical therapy (motor relearning for mobility and balance) one-on-one twice per week for 6 weeks.

  • OtherDalfampridine plus physical therapy

    Dalfampridine (10 mg) every 12 hours for 6 weeks while simultaneously receiving physical therapy (motor relearning for mobility and balance) one-on-one twice per week.

    Also known as: Combined drug and behavioral

06

What researchers measure

Primary outcomes

  1. Change in Timed 25-Foot Walk (T25FW)

    The T25FW is a test that times how long in seconds a person can walk 25 feet from standing start as quickly as possible. We will assess the change in T25FW between baseline and end of treatment for each phase of the treatment (1: dalfampridine only run-in; 1: physical therapy with our without dalfampridine)

    Time frame: Week 0 to week 6, week 8 to week 14

07

Study locations

1 of 1 sites recruiting
  • MGH Institute of Health Professions
    Boston, Massachusetts 02129, United States
    Recruiting
    • Prudence Plummer, PhD · Contactpplummer@mghihp.edu · 617-724-3103
    • Prudence Plummer, PhD, PT · Principal investigator
    • Eric Klawiter, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for May 2027, 32 months after the start.

Of 96 phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 32 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Jun 2024 → Sep 2024, primary completion Dec 2026 → May 2027 and completion Dec 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Nov 18, 2023
StartActual
Sep 20, 2024was Jun 2024
Primary completionEst.
May 2027was Dec 2026
CompletionEst.
Jul 2027was Dec 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 12, 2024→Sep 20, 2024
Nov 6, 2026
Primary completion
Dec 2026→May 2027
Nov 6, 2026
Study completion
Dec 2026→Jul 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date Jun 12, 2024→Sep 20, 2024
    Primary completion Dec 2026→May 2027
    Study completion Dec 2026→Jul 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06136728
Lead sponsor
MGH Institute of Health Professions
Responsible party
Prudence Plummer (Professor, MGH Institute of Health Professions) — Principal investigator
First posted
Nov 18, 2023
Start date
Sep 20, 2024
Primary completion
May 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Prudence Plummer, PhD
Contact
pplummer@mghihp.edu
617-724-3103
Prudence Plummer, PhD, PT
principal investigator · MGH Institute of Health Professions

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4-Aminopyridine

Start the discussion